Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eganelisib + Nivolumab in Advanced Urothelial Carcinoma
NCT03980041Phase 2Completed
- Sponsor
- Infinity Pharmaceuticals, Inc.
- Start
- Sep 2019
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of eganelisib in urothelial carcinoma (UC), sponsored by Infinity Pharmaceuticals, Inc.. Started Sep 2019; status: completed.
02
Drugs
eganelisib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03980041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03980041.